Business
Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article
Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / January 12, 2021 / Halberd Corp. (OTC PINK:HALB) was recently included alongside Novavax Inc and Moderna Inc in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021. Halberd was noted to be working in a different direction from the vaccine producers. According to the article, with vaccines already receiving pushback from the public, Halberd's prevention and symptom alleviation approach, both pre-infection and post infection, may have a huge impact in the coming weeks and months.Halberd's two monoclonal antibodies against the SARS-Cov-2 spike protein, used together in a "cocktail" provide a potential way to prevent the virus from replicating and thus reducing the severity of the disease, if contracted. Equally important, it creates a mechanism to reduce or even eliminate the symptoms. The antibodies could also potentially be employed as a diagnostic tool.Halberd's Chief Technical Officer, Dr. Patricio Reyes, repeated his earlier comments, "This is very promising. In our in vitro experiments, our unique antibodies demonstrated a high degree of affinity and lysis for infected cells. We are now commencing in vivo studies to demonstrate their efficacy in diagnosing COVID-19 as well as preventing viral replication and multi-organ system damage associated with COVID-19. By eliminating the adverse consequences of contracting the virus, our quest is to make Covid irrelevant altogether."William A. Hartman, Chairman, President & CEO, reiterated, "We believe having multiple antibodies available not only increases our product application options, but also their effectiveness, when used in combination. While there is no definitive proof of efficacy yet, mathematically speaking, if each antibody is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives would be substantially reduced when antibodies work in tandem. The same would be true with regard to the use of antibodies in combination as a therapeutic tool as well as their use as a prophylactic measure in a preventative nasal spray. For this reason, we continue to move forward on the development and testing of the...